Skip to main content
SpringerLink
Log in

Context is a Critical for Psychoactive Drug Effects

  • Commentary
  • Published:
CNS Drugs Aims and scope Submit manuscript

The Original Article was published on 24 November 2023

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pouyan N, Younesi Sisi F, Kargar A, Scheidegger M, McIntyre R, Morrow J. The effects of lysergic acid diethylamide (LSD) on the positive valence systems: A Research Domain Criteria (RDoC)-informed systematic review. CNS Drugs. 2023;37:12. https://doi.org/10.1007/s40263-023-01044-1.

    Google Scholar 

  2. Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, et al. Psychedelics and the essential importance of context. J Psychopharmacol. 2018;32:725–31.

    Article  PubMed  Google Scholar 

  3. Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, et al. The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology. 2018;235:505–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22:603–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kaelen M, Barrett FS, Roseman L, Lorenz R, Family N, Bolstridge M, et al. LSD enhances the emotional response to music. Psychopharmacology. 2015;232:3607–14.

    Article  CAS  PubMed  Google Scholar 

  6. Barrett FS, Preller KH, Herdener M, Janata P, Vollenweider FX. Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. Cereb Cortex. 2018;28:3939–50.

    Article  PubMed  Google Scholar 

  7. Adamska I, Finc K. Effect of LSD and music on the time-varying brain dynamics. Psychopharmacology. 2023;240:1601–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Friesen P. Psychosis and psychedelics: historical entanglements and contemporary contrasts. Transcult Psychiatry. 2022;59:592–609.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Hoch PH. Remarks on LSD and mescaline. J Nerv Ment Dis. 1957;125:442.

    Article  CAS  PubMed  Google Scholar 

  10. Deshon HJ, Rinkel M, Solomon HC. Mental changes experimentally produced by L. S. D. (d-Lysergic acid diethylamide tartrate). Psych Q. 1952;26:33–53.

    Article  CAS  Google Scholar 

  11. Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J Psychopharmacol. 2019;33:1076–87.

    Article  PubMed  Google Scholar 

  12. Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology. 2011;218:649–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. 2016;30:1259–67.

    Article  CAS  PubMed  Google Scholar 

  14. Garel N, Drury J, Thibault Lévesque J, Goyette N, Lehmann A, Looper K, et al. The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Front Psychiatry. 2023;14:1268832.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11:125–36.

    Article  CAS  PubMed  Google Scholar 

  16. van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the Clinician Administered Dissociative State Scale. J Affect Disord. 2018;227:11–6.

    Article  PubMed  Google Scholar 

  17. Ballard ED, Zarate CA. The role of dissociation in ketamine’s antidepressant effects. Nat Commun. 2020;11:6431.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV. Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend. 2014;136:153–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of Consciousness Rating Scale (OAV). PLoS ONE. 2010;5:e12412.

    Article  PubMed  PubMed Central  Google Scholar 

  20. D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol. 2004;29:1558–72.

    Article  Google Scholar 

  21. van Heugten-Van der Kloet D, Giesbrecht T, van Wel J, Bosker WM, Kuypers KP, Theunissen EL, et al. MDMA, cannabis, and cocaine produce acute dissociative symptoms. Psychiatry Research. 2015;228:907–12.

  22. Sanches RF, De Lima OF, Dos Santos RG, Macedo LRH, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36:77–81.

    Article  CAS  PubMed  Google Scholar 

  23. Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry. 2019;10:650.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Holze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology. 2019;45:462–71.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience. 2007;146:509–14.

    Article  CAS  PubMed  Google Scholar 

  26. Edsinger E, Dölen G. A conserved role for serotonergic neurotransmission in mediating social behavior in octopus. Curr Biol. 2018;28:3136-3142.e4.

    Article  CAS  PubMed  Google Scholar 

  27. Molla H, Lee R, Lyubomirsky S, de Wit H. Drug-induced social connection: both MDMA and methamphetamine increase feelings of connectedness during controlled dyadic conversations. Sci Rep. 2023;13:15846.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol. 1993;33:639–76.

    Article  CAS  PubMed  Google Scholar 

  29. Bedi G, Hyman D, de Wit H. Is ecstasy an “empathogen”? effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiat. 2010;68:1134–40.

    Article  CAS  PubMed  Google Scholar 

  30. Corbin WR, Hartman JD, Bruening AB, Fromme K. Contextual influences on subjective alcohol response. Exp Clin Psychopharmacol. 2021;29:48–58.

    Article  PubMed  Google Scholar 

  31. Alboni S, van Dijk RM, Poggini S, Milior G, Perrotta M, Drenth T, et al. Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. Mol Psychiatry. 2017;22:552–61.

    Article  CAS  PubMed  Google Scholar 

  32. Gerevich J, Bácskai E, Farkas L, Danics Z. A case report: pavlovian conditioning as a risk factor of heroin “overdose” death. Harm Reduct J. 2005;2:11.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Siegel S. The heroin overdose mystery. Curr Dir Psychol Sci. 2016;25:375–9.

    Article  Google Scholar 

  34. O’Brien CP, Childress AR, McLellan AT, Ehrman R. A learning model of addiction. Res Publ Assoc Res Nerv Ment Dis. 1992;70:157–77.

    PubMed  Google Scholar 

  35. Pouyan N, Halvaei Khankahdani Z, Younesi Sisi F, Lee Y, Rosenblat JD, Teopiz KM, et al. A Research Domain Criteria (RDoC)-guided dashboard to review psilocybin target domains: a systematic review. CNS Drugs. 2022;36:1031–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Hartogsohn I. American trip: set, setting, and the psychedelic experience in the twentieth century. New York: MIT Press; 2020.

    Book  Google Scholar 

  37. Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry. 2016;3:619–27.

    Article  PubMed  Google Scholar 

  38. Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, Mayo-Wilson E, et al. Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension. JAMA. 2022;328:2252–64.

    Article  PubMed  Google Scholar 

  39. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348: g1687.

    Article  PubMed  Google Scholar 

  40. Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology. 2022;239:1989–2010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Hakak-Zargar B, Tamrakar A, Voth T, Sheikhi A, Multani J, Schütz CG. The utility of research domain criteria in diagnosis and management of dual disorders: a mini-review. Front Psych. 2022;13: 805163.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, McGill University, Montréal, QC, Canada

    Kyle T. Greenway

  2. Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada

    Kyle T. Greenway

Authors
  1. Kyle T. Greenway
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyle T. Greenway.

Ethics declarations

Funding

The author did not receive support from any organization for the submitted work.

Conflict of interest

The author has no relevant financial interests to disclose.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Author’s contributions

KTG authored this article and agrees to be accountable for the work.

Additional information

This comment refers to the article available at https://doi.org/10.1007/s40263-023-01044-1

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greenway, K.T. Context is a Critical for Psychoactive Drug Effects. CNS Drugs 37, 1065–1068 (2023). https://doi.org/10.1007/s40263-023-01053-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-023-01053-0

Search

Navigation